|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10,986.00 GBX | -0.40% |
|
+1.89% | +4.95% |
| Jun. 02 | ASTRAZENECA : Buy rating from JP Morgan | ZD |
| Jun. 02 | UK's FTSE 100 closes around flat as staples, healthcare losses eclipse energy gains | RE |
| Capitalization | 232B 201B 188B 171B 315B 19,934B 357B 2,196B 855B 9,126B 868B 851B 33,363B | P/E ratio 2025 * |
23.4x | P/E ratio 2026 * | 19.4x |
|---|---|---|---|---|---|
| Enterprise value | 252B 218B 204B 186B 342B 21,679B 388B 2,388B 930B 9,925B 944B 925B 36,282B | EV / Sales 2025 * |
4.35x | EV / Sales 2026 * | 4x |
| Free-Float |
96.62% | Yield 2025 * |
2.15% | Yield 2026 * | 2.26% |
More valuation ratios
* Estimated data
More news
Last Transcript: AstraZeneca PLC
| ASTRAZENECA : Deutsche Bank is Neutral | Jun. 04 | ZD |
| ASTRAZENECA : JP Morgan gives a Buy rating | Jun. 03 | ZD |
| ASTRAZENECA : UBS reaffirms its Buy rating | Jun. 03 | ZD |
| ASTRAZENECA : Buy rating from JP Morgan | Jun. 02 | ZD |
| ASTRAZENECA : Receives a Buy rating from JP Morgan | Jun. 02 | ZD |
More press releases
More news
| 1 day | -0.40% | ||
| 1 week | +1.89% | ||
| Current month | +2.48% | ||
| 1 month | +7.92% | ||
| 3 months | -7.54% | ||
| 6 months | +4.95% | ||
| Current year | +4.95% |
| 1 week | 10,696 |  | 11,086 |
| 1 month | 9,932 | | 11,086 |
| Current year | 9,573.5 | | 12,208 |
| 1 year | 9,573.5 | | 13,388 |
| 3 years | 9,461 | | 13,388 |
| 5 years | 6,736 | | 13,388 |
| 10 years | 3,680 | | 13,388 |
| Manager | Title | Age | Since |
|---|---|---|---|
Pascal Soriot
CEO | Chief Executive Officer | 65 | 2012-09-30 |
Aradhana Sarin
DFI | Director of Finance/CFO | 51 | 2021-07-31 |
Sharon Barr
CTO | Chief Tech/Sci/R&D Officer | - | 2023-07-31 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 69 | 1999-04-05 | |
Pascal Soriot
BRD | Director/Board Member | 65 | 2012-09-30 |
Philip Broadley
BRD | Director/Board Member | 64 | 2017-04-26 |
| Name | Weight | AuM | 1st Jan change | |
|---|---|---|---|---|
| 8.29% | 57 M€ | +12.69% | - | |
| 5.39% | 200 M€ | -1.07% | - | |
| 5.17% | 21 M€ | +0.03% | - | |
| 4.89% | 1,138 M€ | +0.29% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -0.40% | +1.89% | -11.35% | +12.37% | 232B | ||
| +0.90% | +6.43% | -7.24% | +181.30% | 736B | ||
| +0.28% | +1.34% | +8.01% | -8.03% | 378B | ||
| -0.58% | +5.27% | -47.31% | +34.04% | 355B | ||
| -0.70% | +0.66% | +14.72% | +37.05% | 338B | ||
| -1.06% | +0.56% | +9.72% | -12.79% | 266B | ||
| -0.93% | +0.08% | +3.08% | +17.37% | 235B | ||
| -0.13% | +3.47% | -36.84% | -3.87% | 205B | ||
| -0.70% | +1.68% | -1.10% | +24.69% | 159B | ||
| -1.21% | +5.10% | -11.25% | -48.78% | 140B | ||
| Average | -0.45% | +2.94% | -7.96% | +23.34% | 304.24B | |
| Weighted average by Cap. | -0.19% | +3.35% | -7.48% | +50.87% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 57.83B 50.09B 46.86B 42.61B 78.56B 4,978B 89.16B 548B 214B 2,279B 217B 212B 8,331B | 61.18B 53B 49.57B 45.09B 83.11B 5,267B 94.33B 580B 226B 2,411B 229B 225B 8,814B |
| Net income | 9.92B 8.59B 8.04B 7.31B 13.47B 854B 15.29B 94.06B 36.64B 391B 37.2B 36.43B 1,429B | 11.95B 10.35B 9.68B 8.8B 16.23B 1,028B 18.42B 113B 44.13B 471B 44.8B 43.88B 1,721B |
| Net Debt | 20.26B 17.55B 16.42B 14.93B 27.53B 1,744B 31.24B 192B 74.85B 799B 75.99B 74.42B 2,919B | 12.88B 11.16B 10.43B 9.49B 17.49B 1,109B 19.85B 122B 47.57B 508B 48.3B 47.3B 1,855B |
More financial data
* Estimated data
Employees
94,300
Sector
Pharmaceuticals
Calendar
| Date | Price | Change | Volume |
|---|---|---|---|
| 25-06-13 | 10,986.00 p | -0.40% | 1,985,957 |
| 25-06-12 | 11,030.00 p | +1.14% | 1,172,368 |
| 25-06-11 | 10,906.00 p | +0.31% | 1,482,294 |
| 25-06-10 | 10,872.00 p | +0.93% | 910,150 |
| 25-06-09 | 10,772.00 p | -0.09% | 629,958 |
Delayed Quote London S.E., June 13, 2025 at 11:35 am EDT
More quotes
Sell
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
149.34USD
Average target price
179.12USD
Spread / Average Target
+19.94%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- AZN Stock
Select your edition
All financial news and data tailored to specific country editions
